DZD6008 trials for Lung cancer

All DZD6008 trials · All Lung cancer trials

Phase breakdown

Recruiting trials studying DZD6008 for Lung cancer

• A Multinational Study Assessing an Oral EGFR Inhibitor, DZD6008 in Patients Who Have Advanced NSCLC With EGFR Mutations (TIAN-SHAN1)
  NCT06905197 · Phase: Phase 1 · Ages: 18 Years and older · Sex: All (male and female) · 5 locations
• Assessing an Oral EGFR Inhibitor, DZD6008 in Patients Who Have Advanced NSCLC With EGFR Mutations (TIAN-SHAN2)
  NCT06813365 · Phase: Phase 1 · Ages: 18 Years and older · Sex: All (male and female) · 1 location
• DZD6008 Combination Therapy in Patients With Locally Advanced or Metastatic NSCLC With EGFR Mutation (TIAN-SHAN7)
  NCT07070440 · Phase: Phase 1, Phase 2 · Ages: 18 Years and older · Sex: All (male and female) · 1 location
• Study of Oral EGFR Inhibitor DZD6008 Combined With Sunvozertinib in Patients Who Have Advanced NSCLC With EGFR Mutations (TIAN-SHAN8)
  NCT07079475 · Phase: Phase 1, Phase 2 · Ages: 18 Years and older · Sex: All (male and female) · 16 locations

Common questions

How many trials study DZD6008 for Lung cancer?

4 recruiting trials.

Is this list complete?

No. For the full record, search ClinicalTrials.gov.